Home/Alligator Bioscience/Denise Goode

DG

Denise Goode

Board Member

Alligator Bioscience

Therapeutic Areas

Alligator Bioscience Pipeline

Drug	Indication	Phase
Mitazalimab	First-line metastatic pancreatic ductal adenocarcinoma (PDAC)	Phase 2
Undisclosed Bispecific Programs	Oncology (unspecified)	Discovery/Preclinical

Leadership Team at Alligator Bioscience

Søren Bregenholt

Chief Executive Officer (CEO)

Chief Financial Officer (CFO)

Hans-Peter Ostler

Chairman of the Board

Eva Sjökvist Saers

Karin Nordbladh

Board Member (Employee Representative)

View full Alligator Bioscience profile